Furthermore, we identified another 3 patients with relapsed AML possessing this unknown CCDC32/CBX3 gene fusion, suggesting it’s not an exclusive event for patient 7; however, our study does not have sufficient data to demonstrate any clinical or experimental value of the AML-related CCDC32/CBX3 fusion, even though this fusion gene impact has been reported in MYCN non-amplified neuroblastoma related dual fusion genes (NB) (Lee et al., 2020). This evidence concerns the gene MYCN and neuroblastoma.